Glasgow, Scotland-based Novosound develops proprietary flexible thin-film ultrasound technology for medical imaging. The venture-backed company currently targets next-generation intravascular ultrasound (IVUS) imaging.
The startup entered into a wearable ultrasound collaboration with Dr. Todd K. Rosengart, a leading U.S. cardiovascular surgeon. Rosengart serves as VP and DeBakey-Bard chair of surgery at Baylor College of Medicine in Texas.
“I have been very impressed with the Novosound technology and how we are applying it to a global clinical need, which we believe will save lives and could indeed become the next vital sign monitor,” Rosengart said in a news release.
Novosound CEO Dr. Dave Hughes said the company continues to make “remarkable progress” in the U.S. He says it ventured into varied sectors like healthcare and wearables with several clients across the tech and renewables and energy spaces.
This follows a previously announced medical imaging collaboration with Pavmed, announced nearly a year ago. Their partnership includes a joint R&D project to incorporate ultrasound technology into an intravascular catheter. This aims to produce cross-sectional images of vascular structures. Novosound also has a partnership with dental company dSound.
“We’re seeing that our R&D partnerships are frequently translating to commercial agreements, and we expect to announce a number of these in 2024,” Hughes said. “Novosound is growing rapidly across our three main sectors – medical, wearables, and industrial monitoring, in North America. On the financials, this equates to us doubling revenue for the fourth year in a row, while adding expertise to the team.
“Overall, we’re demonstrating that we’re at the forefront of ultrasound sensor technology, and our clients are helping us achieve our vision, which we describe as ‘Ultrasound. Integrated. Everywhere.’”